Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1995-3-16
|
pubmed:abstractText |
Complete regression of solid tumors was achieved by plural intravenous (i.v.) administrations of polyethylene glycol (PEG)-modified tumor necrosis factor-alpha (TNF-alpha), prepared by covalently modifying natural human TNF-alpha with N-succinimidyl succinate PEG. The anti-tumor efficacy of PEG-modified TNF-alpha (MPEG-TNF-alpha), in which 56% of the TNF-alpha-lysine residues were coupled with PEG, was compared with that of native TNF-alpha in the Meth-A murine fibrosarcoma model. MPEG-TNF-alpha and native TNF-alpha were given as i.v. injections twice a week for 2 weeks. The anti-tumor activity of MPEG-TNF-alpha was dose-dependent and was far superior to that of native TNF-alpha. Complete regression was observed in 3 of the 8 mice administered native TNF-alpha at the dose of 10,000 JRU (Japan reference unit), but 4 of the 5 remaining mice died during the therapeutic period. At 5,000 JRU of native TNF-alpha, no case of complete regression was observed. By contrast, complete regression was obtained in all 10 mice given 200 JRU of MPEG-TNF-alpha. No side-effects were observed at the dose of 500 JRU of MPEG-TNF-alpha, which was 2.5 times the minimal dose (200 JRU) of MPEG-TNF-alpha required for complete regression in all treated mice. MPEG-TNF-alpha appears to have potential as a candidate anti-tumor therapeutic agent.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/PEG-modified tumor necrosis...,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/tumor-associated transplantation...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0910-5050
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1185-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7852179-Animals,
pubmed-meshheading:7852179-Antigens, Neoplasm,
pubmed-meshheading:7852179-Disease Models, Animal,
pubmed-meshheading:7852179-Dose-Response Relationship, Drug,
pubmed-meshheading:7852179-Drug Screening Assays, Antitumor,
pubmed-meshheading:7852179-Female,
pubmed-meshheading:7852179-Fibrosarcoma,
pubmed-meshheading:7852179-Histocompatibility Antigens,
pubmed-meshheading:7852179-Injections, Intravenous,
pubmed-meshheading:7852179-Mice,
pubmed-meshheading:7852179-Neoplasm Transplantation,
pubmed-meshheading:7852179-Polyethylene Glycols,
pubmed-meshheading:7852179-Remission Induction,
pubmed-meshheading:7852179-Tumor Necrosis Factor-alpha
|
pubmed:year |
1994
|
pubmed:articleTitle |
Intravenous administration of polyethylene glycol-modified tumor necrosis factor-alpha completely regressed solid tumor in Meth-A murine sarcoma model.
|
pubmed:affiliation |
Faculty of Pharmaceutical Sciences, Osaka University, Suita.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|